Philip Morris International Inc.PM

NYSEConsumer EssentialsCigarettes
Price (close)
$191.50
Market cap
$298.7B
P/E
27.5x
Revenue (TTM)
$42.5B
Net income
$10.9B
Dividend yield
3.07%
1-year total return
21.0%
Net margin
25.6%
Revenue growth
8.9%
Debt / equity
—

What Philip Morris International Inc. does.

Philip Morris International Inc. is a Virginia holding company incorporated in 1987. In March 2008, we became a U.S. public company listed on the New York Stock Exchange and subject to the rules of the U.S. Securities and Exchange Commission (the "SEC"). We are a leading international consumer goods company, actively delivering a smoke-free future and evolving our portfolio for the long term to include products outside of the tobacco and nicotine sector. Our current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, nicotine pouch and e-vapor products. Since 2008, we have invested over $16 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This investment includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. In November 2022, we acquired Swedish Match AB ("Swedish Match") – a leader in oral nicotine delivery – creating a global smoke-free combination led by the companies’ IQOS and ZYN brands. As of April 30, 2024, we hold the full rights to commercialize IQOS in the U.S. after reaching an agreement to end our U.S. commercial relationship covering IQOS with Altria Group, Inc. in 2022. Following a robust science-based review, the U.S. Food and Drug Administration (the "FDA") has authorized the marketing of Swedish Match’s General snus and ZYN nicotine pouches and versions of PMI’s IQOS devices and consumables - the first-ever such authorizations in their respective categories. Versions of IQOS devices and consumables and General snus also obtained the first-ever Modified Risk Tobacco Product ("MRTP") authorizations from the FDA. We describe the MRTP orders in more detail in the "Business Environment" section of Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations .

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$28.7B$31.4B$31.8B$35.2B$37.9B$40.6B
Net income$8.1B$9.1B$9.0B$7.8B$7.1B$11.3B
Free cash flow$9.2B$11.2B$9.7B$7.9B$10.8B$10.7B

More on PM.

Figures from Philip Morris International Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.